BXRXQ — Baudax Bio Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $13.91m
- $1.27m
Brief: Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial Of Bx1000
Brief: Baudax Bio To Host Key Opinion Leader Webinar To Discuss Results Of Phase 2 BX1000 Trial
U.S. STOCKS ON THE MOVE-Energy firms, crypto stocks, Walt Disney
U.S. STOCKS ON THE MOVE-Cyclerion, banks, Jounce Therapeutics
Baudax Bio rises on positive interim data from trial
Brief: Baudax Bio Gives Positive Results From 2nd Interim Analysis Of Phase 2 Randomized Trial For BX1000
Brief: Baudax Bio Holds No Cash Deposits Or Securities With Silicon Valley Bank
U.S. STOCKS ON THE MOVE-Baudax Bio , GATX Corp, Verb Technology, Decibel Therapeutics
Baudax gains on positive interim analysis of study data on muscle relaxant drug
Brief: Baudax Bio Announces Positive Outcome Of Interim Analysis Of Phase Ii Randomized Trial For Bx1000
Brief: Baudax Bio Inc - Continues To Evaluate Alternative Approaches To The Monetization Of Anjeso Both In The United States And Outside The United States
U.S. STOCKS ON THE MOVE-Bitfarms, Hoth Therapeutics, Boralex
U.S. STOCKS ON THE MOVE-Tesla, Exxon Mobil, Chevron
Brief: Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 In Patients Undergoing Surgery
Brief: Baudax Bio Announces Closing Of $5 Million Public Offering
Brief: Baudax Bio Announces 1-For-40 Reverse Stock Split
Baudax Bio Inc reports results for the quarter ended in September - Earnings Summary
Brief: Baudax Bio Reports Q3 2022 Results
Baudax Bio Inc expected to post a loss of 53 cents a share - Earnings Preview